title: Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion.
abstract: The important role of ascorbic acid (AA) as an anti-oxidant is particularly relevant in diabetes mellitus where plasma concentrations of AA are reduced. This study was conducted to evaluate the effects of treatment with AA or an aldose reductase inhibitor, tolrestat, on AA metabolism and urinary albumin excretion in diabetes. Blood and urine samples were collected at 0, 3, 6, 9, and 12 months from 20 diabetic subjects who were randomized into two groups to receive either oral AA 500 mg twice daily or placebo. Systolic and diastolic blood pressures, HbA1c, plasma lipids, urinary albumin, and total glycosaminoglycan excretion were measured at all time points, and heparan sulphate (glycosaminoglycan) was measured at 0 and 12 months. The same parameters, as well as urinary AA excretion, were determined at 0 and 3 months for 16 diabetes subjects receiving 200 mg tolrestat/day. AA treatment increased plasma AA (ANOVA, F ratio = 12.1, p = 0.004) and reduced albumin excretion rate (AER) after 9 months (ANOVA, F ratio = 3.2, p = 0.03), but did not change the other parameters measured. Tolrestat lowered plasma AA (Wilcoxon's signed-rank test, p < 0.05), but did not change AER or the other parameters measured. The ability of AA treatment to decrease AER may be related to changes in extracellular matrix or improvement in oxidative defence mechanism. Unlike the rat model of diabetes, inhibition of aldose reductase did not normalize plasma AA or AER in humans. In fact, tolrestat reduced the plasma AA concentration, a phenomenon which may be due to increased utilization of AA. Dietary supplementation of AA in diabetic subjects may have long-term benefits in attenuating the progression of diabetic complications.
authors.affiliation: Department of Life Sciences in Nursing, University of Sydney, Sydney, Australia. amcaulif@mallet.nursing.su.edu.au
authors.forename: A V
authors.initials: AV
authors.lastname: McAuliffe
authors.forename: B A
authors.initials: BA
authors.lastname: Brooks
authors.forename: E J
authors.initials: EJ
authors.lastname: Fisher
authors.forename: L M
authors.initials: LM
authors.lastname: Molyneaux
authors.forename: D K
authors.initials: DK
authors.lastname: Yue
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000188:drug therapy*; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006025:Glycosaminoglycans / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000494:pharmacology*; D010919:Placebos; D011509:Proteoglycans / Q000378:metabolism; D013997:Time Factors
chemical_list: D006025:Glycosaminoglycans; D009281:Naphthalenes; D010919:Placebos; D011509:Proteoglycans; C040550:tolrestat; D000449:Aldehyde Reductase; D001205:Ascorbic Acid